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Crystal structure of MytiLec, a 
galactose-binding lectin from the 
mussel Mytilus galloprovincialis 
with cytotoxicity against certain 
cancer cell types
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Sam-Yong Park1, Yasuhiro Ozeki2 & Jeremy R. H. Tame1
MytiLec is a lectin, isolated from bivalves, with cytotoxic activity against cancer cell lines that express 
globotriaosyl ceramide, Galα(1,4)Galβ(1,4)Glcα1-Cer, on the cell surface. Functional analysis 
shows that the protein binds to the disaccharide melibiose, Galα(1,6)Glc, and the trisaccharide 
globotriose, Galα(1,4)Galβ(1,4)Glc. Recombinant MytiLec expressed in bacteria showed the same 
haemagglutinating and cytotoxic activity against Burkitt’s lymphoma (Raji) cells as the native form. 
The crystal structure has been determined to atomic resolution, in the presence and absence of ligands, 
showing the protein to be a member of the β-trefoil family, but with a mode of ligand binding unique 
to a small group of related trefoil lectins. Each of the three pseudo-equivalent binding sites within 
the monomer shows ligand binding, and the protein forms a tight dimer in solution. An engineered 
monomer mutant lost all cytotoxic activity against Raji cells, but retained some haemagglutination 
activity, showing that the quaternary structure of the protein is important for its cellular effects.
Lectins are non-catalytic glycan-binding proteins, present in all three domains of life, with diverse stereospecific 
carbohydrate binding specificities, functions and protein folds. MytiLec, a lectin isolated from the Mediterranean 
mussel Mytilus galloprovincialis, was identified through a study of marine organisms and their adaptation to dif-
ferent habitats and environmental systems, and shown to bind α-D-galactose and N-acetyl-α-D-galactosamine 
(α-GalNAc)1. The primary structure of MytiLec, with 149 amino acid residues in total (http://www.uniprot.org/
uniprot/B3EWR1), was determined by a protein chemical procedure combining both Edman degradation and 
mass spectrometry. It has three broadly similar repeats of a sequence about 45 residues long, highly conserved at 
certain positions, and a single tryptophan residue near the start of the second repeat. MytiLec has no significant 
sequence similarity to any known protein, except Crenomytilus grayanus lectin (CGL)2 and Mytilus trossulus 
lectin (MTL)3, from two different species of sea mussel, which both share 88% sequence identity with MytiLec. 
The natural function of these proteins appears to be anti-bacterial or anti-fungal, and they show bacteriostatic 
properties. Lectins from Mytilus galloprovincialis are known to be involved in innate immunity by acting as pat-
tern recognition receptors (PRR)4,5. Recently genetics approaches have identified two new related proteins in 
M. galloprovincialis named MytiLec-2 and MytiLec-3, which consist of both a carbohydrate-binding domain 
with a very similar primary structure to MytiLec and a pore-forming aerolysin-like domain6. We have shown1 
that MytiLec binds globotriose (abbreviated Gb3), Galα(1,4)Galβ(1,4)Glc, a component of glycosphingolipids 
that is prevalent on the surface of certain cancer cell types such as Burkitt’s lymphoma7. MytiLec added to such 
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cells down-regulates cell growth and shows dose-dependent cytotoxic effects that are specifically blocked by the 
addition of an α-galactoside1.
Recently there has been a huge increase in interest in the medicinal potential of lectins, particularly as treat-
ments for cancer8, but also as adjuvants or modulators of immune responses9, and anti-viral agents10. Exogenous 
expression of some lectins derived from marine sources has been shown to induce apoptosis in cancer cells11, but 
the marked cytotoxicity of many lectins substantially reduces the possibility of developing them into clinically 
useful formulations. The lectin ABL, from the edible mushroom Agaricus bisporus, combines both strong anti-
proliferative effects on epithelial cancer cells with no apparent cytotoxicity to normal cells12,13. It recognises the 
Thomsen-Friedenreich-antigen (TF-antigen), a well-known disaccharide cell-surface marker for neoplastic cells, 
consisting of a galactose and N-acetyl-D-galactosamine residue connected by a β(1,3) linkage. After uptake into 
human colon cancer cells, ABL appears to block nuclear localization signal-dependent protein uptake into the 
nucleus14. A related lectin has also been isolated from another common edible mushroom, Boletus edulis, and 
named BEL β-trefoil15. The majority of lectins such as ABL and BEL β-trefoil that have been studied for potential 
medical benefits are specific for β-linked saccharides, so MytiLec is of interest for its unusual ligand specificity 
and anti-bacterial properties, as well as its demonstrated effects against certain cancer cell lines.
Although relatively rare, β-trefoil lectins with a specificity for α-linked oliogosaccharides have been structur-
ally characterised, including the agglutinin MOA from the fairy ring mushroom Marasmius oreades, which is spe-
cific for Galα(1,3) Gal-containing saccharides, and can agglutinate group B erythrocytes16,17. The β-trefoil domain 
of MOA is also slightly unusual in having three sugar binding sites related by pseudo-symmetry. To understand 
the ligand specificity and 3-dimensional structure of MytiLec, we have created a bacterial expression system for 
the protein, and solved its structure with crystals diffracting to atomic resolution. Lack of a suitable search model 
with high sequence similarity to MytiLec led us to determine phases experimentally. The conformation of a com-
plex formed by MytiLec with α-GalNAc was also solved, in a different space-group from the apo form.
Results
Overall structure. Apo-MytiLec crystallised in space-group P21, and diffracted to 1.1 Å resolution. The lack 
of an obvious search model led us to determine phases using a heavy atom derivative, which was aided by the 
strong diffraction of the physically robust crystals. Crystallographic data and refinement statistics are given in 
Table 1. Two monomers of MytiLec are found in the asymmetric unit, and the model shows expected geometrical 
Data collection statistics
 Data-set Apo GalNAc Pt
 Space group P21 C2 P21
 Wavelength (Å) 1.1000 0.9800 1.0713
 Unit cell (Å) a = 57.7, b = 41.5 a = 80.3, b = 64.2 a = 57.3, b = 41.7
 c = 68.8, β = 108.5° c = 74.3, β = 121.5° c = 68.2, β = 108.1°
  Resolution range (overall/outer 
shell) 50.0-1.10/1.12-1.10 28.6-1.049/1.088-1.05 50.0-1.79/1.82-1.79
  Reflections (measured/unique) 422,688/120,340 650,349/147,442 133,713/28,579
  Completeness (overall/outer 
shell, %) 96.0/89.6 98.6/97.9 98.4/97.1
 aRmerge (overall/outer shell, %) 10.8/29.8 6.6/41.4 8.5/29.7
 Multiplicity (overall) 3.5 4.4 4.7
  Average I/σ(I) (overall/outer 
shell) 15.3/2.1 34.4/6.2 15.0/4.2
Refinement statistics
 Apo (PDB 3 WMU) GalNAc (PDB 3 WMV)
 Resolution range (Å) 27.48-1.10 28.65-1.05
 bR-factor/free R-factor (%) 13.7/16.3 13.7/15.5
 Rmsd bond lengths (Å)/angles (°) 0.024/2.23 0.024/2.15
 No. water molecules 341 299
  Average B factors (Å2) (protein/
water/ligand) 10.0/24.2/- 8.6/20.9/12.3
  % residues with favoured 
Ramachandran angles 96.7 96.7
  % residues with acceptable 
Ramachandran angles 3.3 3.3
  % residues with outlier 
Ramachandran angles 0 0
Table 1. Crystallographic data statistics. = ∑ ∑ − ∑ ∑I I IRmerge ( )/a hkl hkl i hkl hkl i hkl i, , , where Ihkl,i is the 
intensity of an observation and 〈Ihkl〉 is the mean value of all intensity observations for this reflection. Values in 
parentheses are for the highest resolution shell. bR factor is ∑ − ∑Fo hkl Fc hkl Fo hkl( ) ( ) / ( )hkl hkl , where Fo 
and Fc are the observed and calculated structure factor amplitudes, respectively. The free R factor was calculated 
with 5% of reflections omitted from the refinement.
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features and has no Ramachandran outliers. Comparison of the two partner chains shows no large shifts of equiv-
alent residues in the Ramachandran plot, although several residues show alternative side-chain conformations. 
The structure is well ordered, with the entire main-chain of each monomer visible in the 2mFo-DFc electron 
density map, revealing a β-trefoil fold consisting of three related sub-domains (Fig. 1). Several N-terminal res-
idues remaining from the thrombin-cleavable tag are also present in the apo-MytiLec electron density map, so 
that chain numbering of the apo structure starts at -1 or -3. Each sub-domain of the polypeptide chain essentially 
consists of a four-stranded β-sheet, the last sub-domain having one extra strand at the C-terminus of the protein, 
giving 13 strands in total per chain. Least-squares fitting the Cα atoms of residues 1 to 149 of each chain in the 
apo-MytiLec model gives a rmsd of 0.27 Å. Overlaying 37 central Cα atoms of individual sub-domains from 
within the same chain gives rmsd values no higher than 0.6 Å, indicating a high degree of internal symmetry 
(Supplementary Fig. S1). The two monomers in the asymmetric unit are closely associated by hydrophobic inter-
actions and hydrogen bonds, as shown in Supplementary Tables S1 and S2. PISA18 reports the buried interface 
area between MytiLec monomers to be about 740 Å2 per chain. Two adjacent phenylalanine residues, Phe 93 and 
Phe 94, sit opposite their symmetry mates at the dimer interface (Fig. 2). MytiLec was originally reported to be 
a monomer in solution on the basis of gel filtration1 but analytical ultracentrifugation confirms the protein is a 
tightly-bound dimer, and mutation of Phe 93 and Phe 94 blocks dimerisation (Fig. 3).
In order to understand how MytiLec binds to galactose and GalNAc, and whether the acetyl group contacts 
the protein, co-crystals of MytiLec and GalNAc were grown. These crystals, in space-group C2, diffracted to 
slightly higher resolution than the apo crystals (Table 1), and also had a dimer in the asymmetric unit showing 
Figure 1. The overall structure of MytiLec. (A) The Cα trace of one MytiLec subunit, looking along the 
pseudo-three-fold symmetry axis. The trace is coloured by secondary structure, with α-helices shown as red 
coils and β-strands as yellow arrows. α-GalNAc ligands are shown as sticks with white carbon atoms, and 
the conserved aspartic acid residue at each site is shown as sticks and labelled. The hydrogen bond between 
this aspartate and the ligand is shown as a dashed line. Secondary structure was determined automatically 
by PYMOL46. (B) The MytiLec dimer, viewed down the dyad axis. Each subunit is coloured from blue 
(N-terminus) to orange (C-terminus). α-GalNAc ligands are shown as sticks, with carbon atoms white and 
oxygen atoms red.
Figure 2. Stereo view of the 2mFo-DFc electron density map in the region of the subunit interface of apo-
MytiLec. Carbon atoms are shown in brown for one subunit and white for the other. Oxygen atoms are coloured 
red and nitrogen blue. Residues Phe 93 and Phe 94 from each subunit contribute significantly to the apolar 
interface. The map is contoured at 1 σ.
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identical interactions between partner chains. Six GalNAc molecules were identified in the electron density map, 
and were sufficiently ordered for the electron density map to show a large hole in the centre of each ring (Fig. 4A).
Comparison with other trefoil lectins. MytiLec shows very strong sequence similarity to CGL, and the 
crystal structure of apo-CGL was reported in 201519. This model (PDB 5DUY) was refined to 2.12 Å resolution, 
was solved by molecular replacement using a combination of 39 known trefoil models. MytiLec and CGL show an 
essentially identical protein fold, and Jakob and colleagues used our MytiLec structures to model sugar binding to 
CGL19. More recently, higher resolution models of CGL have been described with several different ligands bound 
including galactosamine and Gb3 allyl20. A sequence alignment of MytiLec and CGL made with ENDscript21 
showing the structural similarity is given in Supplementary Fig. S2. Similar trefoil structures were identified in 
PDB using DALI22. The closest match is CGL with a Z-score of 33.3, but the sequence similarity of all other pro-
tein hits was under 12% overall. The next hit, with Z = 21.2, was an exo-beta-1,3-galactanase from Clostridium 
thermocellum (PDB 3VT1), but the models of this protein are refined to only moderate resolution23. Threefoil, an 
artificial symmetrical β-trefoil was the next best structural match, with Z = 20.824. Agglutinin-II from the bark 
of the elderberry Sambucas nigra is the next highest score (Z = 19.1); it binds the Tn antigen (GalNAc linked to 
serine or threonine), but is mainly monomeric in solution25. The MOA N-terminal trefoil domain shows strong 
similarity to MytiLec (Z = 18.6), but the dimerisation is through the C-terminal domain16. Several dimeric 
β-trefoil lectins are known that, like MytiLec, have no other domains and self-associate by direct interaction of 
the trefoil. Two such proteins, SSA, an agglutinin from the phytopathogenic fungus Sclerotinia sclerotiorum (PDB 
2X2T)26, and BEL β-trefoil (PDB 4I4X)15 were chosen for comparison of the dimerisation interface. Overlaps of 
the monomers were made using secondary-structure matching27. For MytiLec-SSA, 120 residues were fitted with 
12.5% sequence identity and a rmsd of 1.5 Å. For MytiLec-BEL β-trefoil, this fitted 106 residues with about 10% 
sequence identity, and gave a rmsd of 1.7 Å for the Cα atoms. The three proteins are of similar length and show 
highly related topology, the β-strands sitting in closely related positions. The surface structure is substantially 
different however, and the loops are not conserved. Overlaying the models, it can be seen the sugar-binding sites 
are at equivalent topological positions, but the manner of sugar binding is very different, and the residues found at 
the binding sites of MytiLec (described below) are not preserved. SSA shows strong sugar-binding at only one site 
per monomer26, which overlaps a binding site on MytiLec. MytiLec, BEL β-trefoil and SSA have a very different 
manner of dimerisation, so that overlaying a monomer of each protein leaves the partner chains in quite different 
positions (Supplementary Fig. S3). SSA buries about 780 Å2 of largely apolar surface of each chain at the interface; 
the residues involved represent a family specific insertion, conserved among SSA homologues but not found in 
other ricin family (R-type) lectins26. The BEL β-trefoil dimer interface has a similar surface area to that of SSA, 
but the interface is hydrophilic and association is driven by hydrogen bonding15.
Sugar binding sites. The very high-resolution diffraction data allowed the GalNAc ligands to be placed 
unambiguously at three sites per polypeptide, related by the pseudo-symmetry of the protein sequence. The prin-
cipal side-chain contacts made by MytiLec with GalNAc are all charged, with the ligand cradled by three histi-
dines and two carboxyl groups (Fig. 4). Five hydrogen bonds form between the protein and each of the six ligand 
molecules (Fig. 4B). A HxDxH motif is found in each sub-domain (Supplementary Fig. S2), the first histidine 
(His 32, His 80 or His 124) lying against the sugar ligand but making no hydrogen bond with it. MytiLec and CGL 
are highly unusual among β-trefoil lectins in having histidine make this interaction, and not a larger aromatic 
side-chain. The aspartic acid and last histidine of the HxDxH motif make hydrogen bonds with O3 (Fig. 4B). The 
other side of the sugar lies against a conserved HPxGG motif found in each sub-domain, beginning at His 15, His 
63 or His 107. The nitrogen atom of the first glycine residue makes a hydrogen bond with O6 of the ligand, which 
also hydrogen bonds to Glu 118, Asp 26 or Glu 74 in binding sites 1–3 respectively. The axially positioned O4 
atom makes two hydrogen bonds to histidine residues, the first residue of the HPxGG motif and the last one of the 
Figure 3. Sedimentation velocity analytical ultracentrifugation analysis of apo-MytiLec. (A) The native 
protein showed a molecular weight of 34 kDa, indicating a dimer is present in solution, with negligible 
contribution to the sedimentation curves from a component corresponding to the monomer. The concentration, 
c(M), is measured in absorption units (A280). (B) Sedimentation of MytiLec(F93DF94S), showing the mutant 
protein adopts a monomeric form with no dimer present. The monomer form was relatively insoluble compared 
to native protein, necessitating the use of much lower concentration.
www.nature.com/scientificreports/
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HxDxH motif. D-glucose differs from D-galactose only in the position of this epimeric oxygen, so the structure 
implies strong selectivity for galactose over glucose. The C2-N-acetyl group of the ligand points away from the 
protein and makes no significant contact with it, indicating that galactose will bind as well as GalNAc with the 
same binding mode. (Arg 38 of one subunit does make a hydrogen bond to the acetyl of one ligand molecule, but 
the other five ligand molecules do not show this bond, which is presumably not strong.).
In order to observe any changes in the protein on ligand binding, both the apo and GalNAc complex struc-
tures were determined. Both the apo crystal and the co-crystal with ligand were cryo-protected immediately 
prior to flash-cooling by soaking in mother liquor containing 25% glycerol. At such high concentration glycerol 
is able to mimic the ligand binding, but not enough to displace GalNAc. The electron density map is shown in 
Supplementary Fig. S4. Comparing the main chain atoms of a single subunit, the apo and liganded forms show 
a rmsd of up to 0.35 Å, depending on which subunits are compared, indicating that the protein shows no move-
ment on ligand binding. Crystal contacts in the different space-groups also do not apparently distort the protein 
significantly.
From their recent high resolution models of CGL complexes, Liao and colleagues report that the ligand bind-
ing modes of CGL and MytiLec are highly conserved, with only subtle differences between them20. They empha-
sise the importance of certain water molecules that mediate interactions between CGL and ligands, but the water 
structure of MytiLec bound to GalNAc shows differences among sites (even equivalent sites within the asymmet-
ric unit), partly due to nearby crystal contacts, and offers little evidence of tightly held water molecules adding 
significantly to the affinity of binding. One surprising finding is that galactose is recognised as the α-anomer in 
all but one of the CGL ligand binding sites in the asymmetric unit, site 3 of chain A (PDB 5F8W)20, whereas the 
difference electron density map of the MytiLec-GalNAc complex shows no significant occupancy of the β anomer 
at any site. The anomeric hydroxyl group of the galactose β anomer binds to the carbonyl group of Gly 111 in 
CGL20, but this cannot explain the difference since site 3 is completely conserved between CGL and MytiLec, and 
an equivalent hydrogen bond is possible at each site (1–3) in both proteins. (Residue numbering in the CGL mod-
els is shifted by 1 relative to the MytiLec models). In the CGL-galactose crystal structure (PDB 5F8W), it is found 
that a neighbouring molecule comes close to site 3 of CGL, so that Arg 84 of this adjacent protein chain can accept 
a hydrogen bond at its carbonyl oxygen from the galactose β anomer, but not the α-anomer. Possibly this CGL 
Figure 4. Interactions between MytiLec and GalNAc. (A) A stereo figure of the 2mFo-DFc electron density 
map for the refined complex model, covering the molecule of α-GalNAc in binding site 2. Electron density 
is shown at a level of 1 σ. Carbon atoms are shown in yellow for the protein and green for the ligand. Oxygen 
atoms are coloured red and nitrogen blue. The maps shows clear rings even for the histidine side-chains. (B) A 
different view of the same bound ligand as in (A), and with hydrogen bonds shown as orange dotted lines. The 
acetyl group points away from the protein and makes no contact with it. At the binding site shown, His 63 and 
His 84 form hydrogen bonds to the epimeric oxygen O4, ensuring selectivity for galactose over glucose. Asp 
26 of binding site 2 is equivalent to Glu 118 and Glu 74 in binding sites 1 and 3 respectively, and each makes a 
hydrogen bond with O6.
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crystal contact is responsible for the ligand conformation at this location, but clearly the β anomer of galactose or 
GalNAc is not excluded by steric clashes at any site, and the strong preference for the α anomer arises from other 
considerations. Although not found for each GalNAc molecule, a water-mediated hydrogen bond between O1 of 
the ligand and Asp 26 (or equivalent) may contribute to the anomeric selectivity of MytiLec, but as noted above 
the pattern of hydration is ambiguous.
In order to understand how MytiLec might bind disaccharides or longer sugar chains selectively, SSM was 
used to overlap the protein with MOA carrying a branched trisaccharide, Galα(1,3)[Fucα(1,2)]Gal. The overall 
sequence identity between the two proteins is very low, but the backbone atoms fit closely, as indicated by the 
DALI score given above. Although fitting the protein backbone atoms places the reducing galactose residue of 
the MOA ligand over the GlcNAc bound to MytiLec, severe clashes can be seen with the non-reducing galactose 
residue (Fig. 5). The ligand binding site of MytiLec is too small and shallow for extensive contacts with oligo-
saccharide ligands, and the binding of melibiose (Galα(1,6)Glc) suggests that only the non-reducing galactose 
residue is strongly recognised. The structural basis for the selectivity for α-linked saccharides can be explained 
by attempting to fit TF-antigen, Galβ(1,3)GalNAcα, to the MytiLec model (Fig. 6). The model of TF-antigen was 
taken from the high-resolution structure of BEL β-trefoil15. An in-house program called CFIT (JRHT, unpub-
lished) was used to make least-squares superpositions of the carbon atoms of one or other residue of TF-antigen 
with the GalNAc bound to MytiLec. Fitting the N-acetyl-D-galactosamine residue of TF-antigen over the MytiLec 
ligand gave severe clashes with the aspartic acid of the HxDxH motif. Fitting the galactose residue of TF-antigen 
Figure 5. An overlap of liganded MOA and Mytilec monomers. Superposition was carried out with SSM27. 
The program selected 130 residues for overlap, with only 9.2% sequence identity, giving an rmsd of 1.7 Å. The 
carbon atoms of MytiLec and the GalNAc ligand are shown in yellow and white respectively. MOA and the 
blood group B trisaccharide, Galα(1,3) [Fucα(1,2)]Gal, are coloured with pink and pale green carbon atoms 
respectively17. The figure shows a close-up of site 1. Residue numbers for MOA are shown in an italic font. It can 
be seen that the non-reducing galactose residue of the trisaccharide overlaps the GalNAc bound to MytiLec, but 
Asp 34 of MytiLec clashes severely with the reducing Gal residue. Equivalent clashes are seen at each MytiLec 
binding site. Overall the binding sites of the two proteins are very different, with MOA having a much more 
extended surface loop, and Trp 35 (MOA) replacing His 32 (MytiLec). Behind Trp 35, it can be seen that His 15 
of MytiLec is replaced by Asp 20 in MOA.
Figure 6. Structural basis of selectivity for α-linked substrates. This stereo view of GalNAc bound to 
MytiLec shows the carbon atoms of the ligand in white, and the anomeric oxygen atom is indicated by an orange 
arrow. TF-antigen, Galβ(1,3)GalNAc, overlapped onto the ligand is shown with carbon atoms coloured purple. 
Least-squares fitting matched the six carbon atoms of the galactose residue of TF-antigen, taken from PDB 
4I4X, to equivalent atoms in the MytiLec-bound GalNAc. This causes strong clashes between the GG motif of 
the protein and the GalNAc residue of TF-antigen due to the β-linkage.
www.nature.com/scientificreports/
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instead gave a better fit, but the extra residue showed strong steric clashes with the glycine-glycine dipeptide 
on the opposite side of the binding site (Fig. 6). The model suggests that MytiLec should be able to bind linear 
oligosaccharides with galactose or GalNAc at the non-reducing end, given an appropriate α-linkage to the next 
residue in the chain.
To confirm the binding specificities implied by the structural model, ITC was used to measure the affinity 
of MytiLec for different small sugar ligands, fitting the binding curve to a simple model with one type of inde-
pendent site. GalNAc was found to bind with a Kd of 0.13 mM, and galactose with a Kd of 0.20 mM. A repre-
sentative thermogram for GalNAc binding to MytiLec is shown in Supplementary Fig. S5, but the monomer 
mutant, MytiLec-F93DF94S, proved too insoluble for study by ITC. Glucose and derivatives were not found to 
bind MytiLec.
Cytotoxicity and haemagglutination activity of the dimer and monomer forms of MytiLec. The 
presence of six ligand binding sites per protein molecule suggests that the multivalency may be functionally rel-
evant. The monomer mutant MytiLec-F93DF94S possessed weak haemagglutination activity, around 10 times 
less than that of the dimer (Fig. 7A). Recombinant MytiLec (dimer) strongly reduces the viability of Burkitt’s 
lymphoma cells, with the same activity as native MytiLec, but MytiLec-F93DF94S (monomer) shows no cytotoxic 
activity at all (Fig. 7B). The three sugar binding sites of the monomer alone are apparently insufficient for the pro-
tein to kill suitable target cell lines, and the quaternary structure of the protein also plays a role in its cytotoxicity.
Discussion
The ligand binding mode for MytiLec and the closely related CGL appears to be novel among β-trefoil lectins. 
Almost all such proteins have a phenylalanine or tyrosine side-chain lying against the apolar face of the ligand, 
a feature missing from MytiLec and replaced with the first histidine of the HxDxH motif. The sugar binding 
sites of MytiLec are well conserved in CGL, but not perfectly (Supplementary Fig. S6). The structure of the 
MytiLec-GalNAc complex suggested that MytiLec may have slightly higher ligand affinity than CGL due to the 
replacement of Glu 118 and Asp 26 with asparagine in CGL, at sites 1 and 2 respectively, weakening the hydrogen 
bond with O6 of the ligand (Fig. 4B). However, Liao and colleagues have recently reported experimental affinities 
of galactose for the three different sites on CGL using NMR, and shown that site 1 has a much higher affinity 
(Kd 178 μM) than sites 2 or 3 (Kd 1288 μM and 815 μM, respectively); these data show no correlation with the 
presence of residues Asn 119, Asn 27 and Glu 75 at sites 1, 2 and 3 respectively of CGL. Their NMR experiments 
detected notable chemical shifts in only four site 1 residues (Ser 22, Ile 36, His 37 and Glu 38), whereas six or 
seven residues were affected at the other sites20. Possibly the weaker binding at sites 2 and 3 is due to slightly 
greater flexibility in the unliganded state, which incurs a free energy penalty to ligand binding, but such effects are 
not visible in the cryo-cooled MytiLec structures, despite the very high resolution, and further studies of mutants 
are required to determine the factors controlling the observed ligand affinity. Liao and colleagues also determined 
the structure of CGL with Gb3 allyl bound, and showed that the Gal1 residue makes the same interactions as 
galactose, but sites 1 and 2 have additional hydrogen bonds to Gal2 through Asn 119 and Asn 27 respectively20. 
They also suggest that Tyr 18 and Tyr 66 (but not the site 3 equivalent of Lys 110) contribute to Gb3 binding 
through water-mediated hydrogen bonds to Gal2. Biolayer interferometry showed Gb3 allyl binds CGL with a 
site-averaged Kd about three-times lower that that of galactose20. Both Tyr 18 and Tyr 66 residues are replaced 
in MytiLec, which shares Lys 110 with CGL, suggesting a lower affinity of MytiLec for Gb3, but the pattern of 
interactions is not entirely uniform at each site of the CGL-Gb3 complex (PDB 5F90). A comparison of MytiLec 
and CGL binding to Gb3 is shown in Supplementary Fig. S6. Kovalchuk and colleagues have built a homology 
model of CGL based on the structure of the MytiLec-GalNAc complex described here (PDB 3WMV), and used 
Figure 7. Haemagglutination activity and cell viability of recombinant MytiLec. (A) Haemagglutination 
titre of MytiLec. White and grey bars indicate haemagglutination titre of monomer MytiLec(F93DF94S) and 
native (dimeric) MytiLec, respectively. (B) Cell viability of Burkitt lymphoma Raji cells treated with MytiLec. Cell 
viability was determined using WST-8 assay. Raji cells were treated with various concentrations (0–50 μg/ml) of 
MytiLec. White bars and grey shaded bars indicate the viability of cells treated with monomer or dimer MytiLec, 
respectively. Error bars show the standard error from three duplicates.
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this model of ligand-bound CGL to mutate the binding sites individually28. Replacing the HPxGG motifs with 
AAxAG motifs at the first two ligand binding sites abolished haemagglutination and mucin binding, but eliminat-
ing the third binding site left residual activity, which is consistent with some role for Asn 27 and Asn 119 of CGL 
in binding the second sugar residue of cognate ligands. The MytiLec and CGL models show that the third binding 
site of each subunit lies on the same side of the dimer, whereas haemagglutination will presumably be promoted if 
attachment to one cell does not sterically hinder attachment to a second. Steric effects as well as multivalency and 
ligand affinity are apparently important influences on the cytotoxic activity of the protein.
The β-trefoil is a common fold, with many structures of widely divergent sequence known. Recently this 
domain family has been the subject of efforts by different groups to create symmetrical variants to help under-
stand protein folding and evolution24,29,30. Lectins in this family are also known as R-type carbohydrate recogni-
tion domains (CRDs) after ricin, the toxin from castor beans. R-type CRDs occur widely among plants, animals 
and prokaryotes, either as part of larger polypeptides or as independent proteins, and over 8000 such sequences 
are known. Pierisin, from the larvae of the cabbage butterfly Pieris rapae, has three R-type lectin domains and an 
ADP-ribosyltransferase domain31, whereas MOA has two α-galactoside-binding R-type lectin domains and one 
serine protease domain. In both cases the non-lectin domain induces cell death17,32, but several β-trefoil lectins 
are known with no accessory domains that still have growth suppression activity against microorganisms or can-
cerous cells33,34. The sequence of MytiLec is sufficiently unusual for automated family assignment by Pfam35 or 
SMART36 to fail to recognize it as a ricin-type trefoil. The crystal structure described here reveals five amino acids 
in each subdomain that bind the hydroxyl-groups at the C3, C4 and C6 positions of galactose, and these binding 
sites (of MytiLec and its homologues CGL and MTL) appear to be quite unrelated to those of any other known 
lectin. A large majority of β-trefoil lectins bind to β-galactoside, but functional analysis shows that MytiLec 
prefers α-galactosides, and this ligand binding is required for the specific cytotoxic effects against certain cancer 
cell lines1. The molecular model directly explains this unusual ligand specificity, and why D-Gal and D-GalNAc 
are both recognized by MytiLec, since the protein does not interact strongly with groups at the C2 position of the 
sugar ligand. TF antigen is a well-known cancer cell marker saccharide that has galactose at the non-reducing 
end, like Gb3, but the MytiLec structure shows that it is unlikely to bind. MytiLec is somewhat unusual in binding 
ligand at each subdomain, and it forms a dimer in solution, giving a total of six ligand sites per protein. The fact 
that an artificial monomeric MytiLec showed weak haemagglutinating activity but no significant cytotoxicity 
against Raji cells indicates that the multivalent dimeric form of MytiLec is crucial for the cytotoxic effect. Recent 
studies have shown that MytiLec enters sensitive cells and initiates programmed cell death through multiple 
pathways including MAPK cascade and caspase activation37. Gb3 is a cell-surface marker found in several differ-
ent cancer cell lines, which suggests that MytiLec and CGL may prove a useful basis for the development of new 
diagnostic agents or treatments for a variety of cancer types.
Methods
Cloning. A synthetic gene encoding MytiLec was designed with flanking NdeI and BamH1 restriction sites. 
Codon optimisation was performed using the back-translation tool from Entelechon, and the gene was syn-
thesised by Operon. The initial reported residue of MytiLec is threonine. This was changed to alanine so that 
expression of the native sequence would result in efficient removal of the N-terminal methionine, but expression 
with an N-terminal histidine tag was exclusively used for protein production. The initiator methionine residue 
is numbered zero, in accordance with the UNIPROT entry B3EWR1. The designed DNA sequence was excised 
from the supplied plasmid DNA and inserted into appropriately cut pET28, using T4 DNA ligase (Wako) at room 
temperature for 1 h. The ligation mixture was used to transform E. coli DH5α, and pET28b-MytiLec was prepared 
from cultures using QIAprep (Qiagen). This vector directs expression of full-length MytiLec carrying a throm-
bin-cleavable hexa-histidine tag at the N-terminus. The final purified protein product, after tag removal, has a 
sequence beginning with GSHMATF.
Expression and purification. pET28b-MytiLec was transformed into E. coli BL21(DE3) RILP, and cells were 
grown at 310 K with shaking in 6 litres of LB medium containing kanamycin and chloramphenicol (20 μg/ml). 
When the O.D. 600 of the culture reached 0.6 ~ 0.7, MytiLec expression was induced by adding IPTG to a final 
concentration of 0.1 mM, and growth was continued overnight at 293 K. The cells were collected by centrifuga-
tion at 3000× g at 277 K for 30 min. The pellet was suspended in 100 mM Tris HCl pH 8.0/0.15 M NaCl/20 mM 
imidazole and then lysed by sonication on ice. The lysate was centrifuged at 38,000× g at 277 K for 50 min. The 
supernatant solution was loaded onto a 10 ml volume nickel-sepharose column (GE Healthcare) equilibrated 
with 100 mM Tris HCl pH 8.0, 0.15 M NaCl, 20 mM imidazole, and after washing, eluted with 20 mM Tris HCl 
pH 8.0, 500 mM imidazole, 150 mM NaCl. The major protein fractions were collected and digested with throm-
bin overnight at 277 K during dialysis into 20 mM Tris HCl pH 7.4/50 mM NaCl. The protease:MytiLec ratio was 
1:200. The protein was re-loaded onto the washed nickel-sepharose column and eluted with 20 mM Tris HCl pH 
7.4/50 mM NaCl. The pooled fractions containing MytiLec were dialysed into 20 mM Tris HCl pH 7.4/50 mM 
NaCl before loading onto an SP-sepharose column (GE) equilibrated with the same buffer, and eluted with a gra-
dient to 1 M NaCl. The pooled protein fractions were concentrated to 10 mg/ml using Amicon centrifugal filter 
units (Millipore).
Analytical Ultracentrifugation. Sedimentation velocity experiments were carried out using an Optima 
XL-I analytical ultracentrifuge (Beckman-Coulter) using an An-50 Ti rotor. Cells with a standard Epon 
two-channel centre-piece and sapphire windows were used. 400 μl of the sample and 420 μl of the reference 
solution (50 mM potassium phosphate pH 7.4 and 0.1 M NaCl) were loaded into the cell. The rotor was kept 
stationary at 293 K in the vacuum chamber for 1 h prior to each run for temperature equilibration. Absorbance 
at 280 nm scans were collected at 10 min. intervals during sedimentation at 50,000 rpm. The resulting scans were 
www.nature.com/scientificreports/
9Scientific RepoRts | 6:28344 | DOI: 10.1038/srep28344
analysed using the continuous distribution c(s) analysis module in the program SEDFIT38. Frictional ratio (f/fo) 
was allowed to float during fitting. The c(s) distribution was converted into a molar mass distribution c(M). Partial 
specific volume of the protein, solvent density, and solvent viscosity were calculated from standard tables using 
the program SEDNTERP39.
Crystallisation and structure determination. Crystallisation experiments were performed at 293 K 
using the hanging-drop vapor diffusion method. Crystals grew in 24% (w/v) PEG 4000, 20 mM sodium acetate, 
0.1 M HEPES pH 7.5, 1% glycerol. Crystals were washed briefly in mother liquor containing 18.5% glycerol as 
cryo-protectant before being stored in liquid nitrogen. Data were collected at beam-line 1A of the Photon Factory, 
Tsukuba. Data were also collected from a crystal which had been soaked for 3 h in 0.5 mM K2PtCl4. A total of 250 
images of 1° oscillation were collected for the native dataset, and 720 images for the derivative. Data processing 
and scaling were carried out with HKL2000 and SCALEPACK40. Two molecules were found in the asymmetric 
unit of the native structure. Eight platinum ions were located for the derivative, none with occupancy above 30%. 
Phases were calculated by SAD using PHENIX41, giving a mean FOM of 0.269. Model building was carried out 
with the Autobuild module42. Manual modifications were carried out with COOT43. Refinement was carried out 
with REFMAC44 and the CCP4 suite45. Non-crystallographic symmetry restraints and TLS group refinement 
were not applied. Isotropic temperature factors were refined with default isotropic restraints giving an R-factor 
around 15%. Finally anisotropic temperature factors were refined, dropping both the R-factor and free R-factor 
2%. Water molecules were checked manually for steric clashes or unusually shaped electron density; several were 
fitted with partial occupancy. Water molecules were removed from the model if their refinement with aniso-
tropic temperature factors proved unstable. Six glycerol molecules were identified by eye in the apo-MytiLec 
structure and refined with expected geometrical features. Figures were prepared with PYMOL46. Co-crystals of 
MytiLec were grown using 10 mg/ml protein with 5 mM N-acetyl-D-galactosamine. The reservoir solution con-
tained 0.2 M potassium thiocyanate, 0.1 M bisTris-propane pH 8.5 and 20% PEG 3350. 25% glycerol was added 
to the reservoir solution for soaking crystals prior to cryo-cooling. Data were collected and processed similarly 
to the apo data-set. The complex structure was determined by molecular replacement from the apo model, and 
refined in a similar manner. Six molecules of N-acetyl-D-galactosamine were found bound to a protein dimer in 
the asymmetric unit of the complex structure, and all of them were refined as fully occupied. Data collection and 
refinement statistics are shown in Table 1.
Creation of the Mytilec monomer mutant. MytiLec(F93DF94S) was produced by introducing both 
mutations simultaneously with a simple PCR procedure using Primestar polymerase. Overlapping 5′ and 3′ 
regions of the gene were amplified from the wild-type gene in pET28 using standard T7 promoter and T7 termi-
nator primers, and two mutagenic primers: fw: CTATTCGCGATGGATTCTGACAATGATAACATTATACAC 
and rv: GTGTATAATGTTATCATTGTCAGAATCCATCGCGAATAG. The two reaction products were then 
combined and used as template for a third PCR reaction with only T7 primers present. The final reaction product 
was purified and cut with NdeI and BamH1 to ligate it into suitably cut pET28. Expression and purification of the 
mutant were carried out essentially as for the wild-type protein.
Purification of native MytiLec. Native MytiLec was purified from the Mediterranean mussel Mytilus gal-
loprovincialis using affinity chromatography by melibiosyl-agarose gel as previously reported1.
Haemagglutination activity assays of dimeric and monomeric MytiLec. Haemagglutination assays 
were performed in 96-well U-shape plates as described previously47. 20 μl of a 2-fold dilution of each recombinant 
MytiLec (native dimer or mutant monomer, 20 mg/ml starting concentration) in TBS was mixed with 20 μl of a 
1% suspension (with TBS; v/v) of fresh rabbit erythrocytes that was washed by saline. The plate was incubated at 
room temperature for 1 h, and the formation of a sheet (agglutination-positive) or dot (agglutination-negative) 
was observed and scored against the lectin titre.
Cytotoxicity of recombinant MytiLec. Raji cells were maintained in RPMI 1640 medium supplemented 
with heat-inactivated fetal calf serum 10% (v/v), penicillin (100 IU/ml), and streptomycin (100 μg/ml) at 310 K 
in an atmosphere of 95% air/5% CO2. Cytotoxic activity and cell growth were determined using Cell Counting 
Kit-8 containing WST-8 (Dojindo Molecular Technologies Inc., Kumamoto, Japan)31,48. Cells (2 × 104, in 90 μl 
solution) were seeded into a 96-well flat-bottom plate and treated with various concentrations of the recombinant 
MytiLec (native dimer or monomer mutant; 10 μl of 0–50 μg/ml) for 24 h at 310 K. The effect on cell growth was 
assayed by addition of WST-8 solution (10 μl) to each well and incubation for 4 h at 310 K. The reduction in the 
proportion of living cells was assayed by measurement of absorbance at 450 nm (relative to reference absorbance 
at 600 nm) using the GLOMAX Multi Detection System (Promega, Madison, WI USA). Results of experiments 
are presented as the mean ± standard error. Differences in means were evaluated by two-tailed Student’s t-test 
with P values < 0.05.
Isothermal titration calorimetry. ITC experiments were carried out with a MicroCal VP-ITC (Malvern). 
20 μM MytiLec (in 10 mM HEPES pH 7.4, 100 mM NaCl) was placed in the cell, and maintained at a temperature 
of 298 K. Ligand was dissolved in the same buffer to a final concentration between 5 mM and 10 mM. 22 injections 
of ligand, 10 μl each, were made in total, allowing the baseline to stabilise between injections. The raw data were 
fitted to a single site model using the manufacturer’s software.
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